WALTHAM, Mass. / Aug 18, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2025 Wells Fargo Healthcare Conference Wednesday, September 3, 2025 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2025 Baird Global Healthcare Conference Tuesday, September 9, 2025 2:35 p.m. ET – Steve Willoughby, senior vice president, investor... Read More

Innovative plate-based internalization reagents designed to deliver accurate, high-throughput, and scalable insights for GPCR and ADC research WALTHAM, Mass. / Aug 06, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of pHSense™ reagents, a powerful technology designed to advance internalization studies in drug discovery. pHSense reagents are designed for high-throughput, plate-based workflows... Read More

Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance WALTHAM, Mass. / Jul 28, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago.... Read More

WALTHAM, Mass. / Jul 24, 2025 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Jul 07, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2025 financial results prior to market open on Monday, July 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To... Read More

Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows WALTHAM, Mass. / Jun 02, 2025 / Business Wire / Revvity, Inc . (NYSE: RVTY), today announced the launch of three Mimix™ reference standards for IVD use, designed for monitoring of next-generation sequencing (NGS) or droplet digital polymerase chain reacting... Read More

The IDS i20 platform offers fully automated processing of specialty assays in endocrinology, allergy, autoimmune and infectious diseases, Alzheimer’s disease and therapeutic drug monitoring WALTHAM, Mass. / May 19, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of its new IDS i20 ™ analytical random access platform from EUROIMMUN, enabling full automation of chemiluminescence immunoassays... Read More

WALTHAM, Mass. / Apr 30, 2025 / Business Wire / Revvity, Inc . (NYSE: RVTY), today announced it will present at the following investor conferences: Bank of America Global Healthcare Conference 2025 Tuesday, May 13, 2025 9:20 a.m. PT - Max Krakowiak, senior vice president and chief financial officer Goldman Sachs 46 th Annual Global Healthcare Conference Tuesday, June 10, 2025 8:00 a.m. ET - Prahlad Singh, president and chief... Read More

Revenue of $665 million; 2% reported growth; 4% organic growth GAAP EPS of $0.35; Adjusted EPS from continuing operations of $1.01 Reaffirms full year 2025 organic growth and adjusted EPS guidance WALTHAM, Mass. / Apr 28, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended March 30, 2025. The Company reported GAAP earnings per share of $0.35, as compared to $0.21 in... Read More

WALTHAM, Mass. / Apr 24, 2025 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2025 to all shareholders of record at the close of business on July 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Apr 03, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To... Read More

FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass. / Apr 02, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test . Initially launched outside the U.S. in 2024, this powerful combination allows... Read More

New agreement to support newborn health adds sequencing lab services to the existing extraction services collaboration WALTHAM, Mass. / Mar 20, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced an agreement with Genomics England to further collaborate on the Generation Study . Under the new contract, Revvity will now also provide DNA sequencing services to help screen newborns for rare genetic conditions.... Read More

Company expands infectious disease diagnostics portfolio with first of several assays validated for dried blood spots as sample material WALTHAM, Mass. / Mar 03, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN’s... Read More

WALTHAM, Mass. / Feb 20, 2025 / Business Wire / Today, Revvity, Inc . (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software Group (CSG) related to the Spotfire ® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted... Read More

WALTHAM, Mass. / Feb 20, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46 th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45 th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh,... Read More

Fourth quarter revenue of $729 million; 5% reported growth; 6% organic growth Fourth quarter GAAP EPS of $0.78; Adjusted EPS from continuing operations of $1.42 Initiates full year 2025 guidance WALTHAM, Mass. / Jan 31, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. Fourth Quarter 2024 The Company reported GAAP earnings per... Read More

WALTHAM, Mass. / Jan 23, 2025 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 9, 2025 to all shareholders of record at the close of business on April 18, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions,... Read More

WALTHAM, Mass. & SAN DIEGO / Jan 13, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced a strategic agreement to commercialize an in vitro diagnostic (IVD) workflow solution for neonatal sequencing, co-developed with Element Biosciences, Inc. , a life science company democratizing access to advanced DNA and multi-omic sequencing solutions. This initiative builds upon Revvity's recent introduction of an... Read More

WALTHAM, Mass. / Jan 12, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its fourth quarter and full year 2024 financial results prior to market open on Friday, January 31, 2025. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the... Read More

WALTHAM, Mass. / Jan 10, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for EUROIMMUN’s automated chemiluminescence-based immunoassay (ChLIA) test for free testosterone. This innovative test is the first of its kind to receive FDA clearance for direct quantitative measurement of free testosterone levels, marking a... Read More

WALTHAM, Mass. / Dec 17, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 43 rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page . A replay of the... Read More

WALTHAM, Mass. / Nov 20, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties’ long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England’s renowned research programs,... Read More

The TotalSeq Phenocyte solution supports robust study of cellular heterogeneity and rare cell types in complex samples at a single cell level SAN DIEGO / Nov 19, 2024 / Business Wire / Scale Biosciences (Scale Bio TM ), a leader in innovative and scalable single cell analysis solutions, and Revvity’s (NYSE: RVTY) BioLegend business, a leading provider of world-class biological reagents and tools, today announced the... Read More

WALTHAM, Mass. / Nov 19, 2024 / Business Wire / Revvity, Inc . (NYSE: RVTY), will present at the 7 th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here . A live audio webcast will be available on the Events section of the... Read More

WALTHAM, Mass. / Nov 18, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity’s senior management team on the Company’s key business initiatives, operational achievements and future financial outlook. The Company also announced strategic adjustments to its operating model to unlock... Read More

Revenue of $684 million; 2% reported growth; 2% organic growth GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 Raises full year 2024 adjusted EPS guidance Authorizes new $1 billion share repurchase program To host Investor Day on November 21st WALTHAM, Mass. / Nov 04, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended September 29, 2024. The... Read More

WALTHAM, Mass. / Oct 24, 2024 / Business Wire / The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 7, 2025 to all shareholders of record at the close of business on January 17, 2025. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health... Read More

Enables transcription of handwritten test request forms to digitized format Utilizes innovative AI for higher accuracy and efficiency Data is securely processed with ISO27001 compliant solution WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced the launch of Revvity Transcribe AI , an innovative optical character recognition (OCR) service designed to convert handwritten text on test... Read More

WALTHAM, Mass. / Oct 22, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today unveils its annual Impact Report , a declaration of the Company’s sustainability, social and governance strategy, initiatives and performance. The report showcases Revvity’s continued evolution and strengthened commitments to creating a lasting, positive impact on the world. “Whether it’s from developing groundbreaking solutions that drive... Read More

WALTHAM, Mass. / Oct 07, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2024 financial results prior to market open on Monday, November 4, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.... Read More

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s WALTHAM, Mass. / Oct 02, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTime TM APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene. APOE genotyping is valuable to assess a... Read More

WALTHAM, Mass. / Aug 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in September 2024: 2024 Wells Fargo Healthcare Conference – Boston, MA Wednesday, September 4, 2024 8:45 a.m. ET - Max Krakowiak, senior vice president and chief financial officer 2024 Baird Global Healthcare Conference – New York City, NY Tuesday, September 10, 2024 12:15 p.m. ET... Read More

Revenue of $692 million; (2)% reported growth; (1)% organic growth GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 Raises full year 2024 adjusted EPS guidance WALTHAM, Mass. / Jul 29, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended June 30, 2024. The Company reported GAAP earnings per share of $0.45, as compared to $0.28 in the same period a... Read More

WALTHAM, Mass. / Jul 25, 2024 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 8, 2024 to all shareholders of record at the close of business on October 18, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Jul 09, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2024 financial results prior to market open on Monday, July 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To... Read More

WALTHAM, Mass. / May 28, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 45 th Annual Goldman Sachs Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. ET in Miami, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here . A live audio webcast will be available on the Events section of the... Read More

Revenue of $650 million; (4)% reported growth; (3)% organic growth First quarter GAAP EPS of $0.21; Adjusted EPS from continuing operations of $0.98 Reaffirms full year 2024 organic growth and adjusted EPS guidance WALTHAM, Mass. / Apr 29, 2024 / Business Wire / Revvity, Inc . (NYSE: RVTY), today reported financial results for the first quarter ended March 31, 2024. The Company reported GAAP earnings per share of $0.21, as... Read More

WALTHAM, Mass. / Apr 25, 2024 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Apr 25, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its strategic priorities. To register, click here . A live audio webcast will be available on the Events section of the... Read More

New and improved workflow now available that pairs Revvity’s T-SPOT™.TB test with the Auto-Pure 2400 liquid handling platform Substantially lowers hands-on time, allowing for increased lab productivity WALTHAM, Mass. / Apr 24, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced the launch of the Auto-Pure 2400 liquid handler from Allsheng for use with the T-SPOT.TB test . The Auto-Pure 2400 platform is easy to... Read More

New CRO system-level expansion elevates data stewardship and enables organizations to gain more insight with less oversight WALTHAM, Mass. / Apr 15, 2024 / Business Wire / Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals , will launch Signals Synergy TM , a software solution designed to drive greater collaboration, project management, and data exchange between... Read More

WALTHAM, Mass. / Apr 04, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2024 financial results prior to market open on Monday, April 29, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To... Read More

WALTHAM, Mass. / Apr 02, 2024 / Business Wire / Today, Revvity, Inc . (NYSE: RVTY) announced that the Massachusetts Superior Court has granted a preliminary injunction compelling Cloud Software Group (CSG) to comply with its contractual obligations under its strategic partner agreements with Revvity, including an order to cease all marketing, selling and support activities in Revvity’s exclusive markets and to continue... Read More

Asserts CSG has acted in bad faith, ignoring obligations as strategic partner for Spotfire® software WALTHAM, Mass. / Mar 20, 2024 / Business Wire / Today, Revvity, Inc . (NYSE: RVTY) announced that it has filed a complaint against Cloud Software Group (CSG) in Massachusetts Superior Court and requested injunctive relief to enforce Revvity’s rights and CSG’s obligations as a strategic partner. CSG is refusing to honor its... Read More

Next-generation suite enhances research productivity and innovation across chemical, pharmaceutical, and biotechnology industries and academia Seamless integration within Revvity Signals Research platform empowers multidisciplinary discoveries WALTHAM, Mass. / Mar 18, 2024 / Business Wire / Today, Revvity, Inc. (NYSE: RVTY) announced that its software and informatics division, Revvity Signals Software , is introducing the... Read More

WALTHAM, Mass. / Feb 21, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the following investor conferences in February and March 2024: Citi's 2024 Unplugged MedTech and Life Sciences Access Day - New York City, NY Thursday, February 29, 2024 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 44 th Annual Health Care Conference – Boston, MA Monday,... Read More

Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements Seamless integration with Spotfire ® for powerful visual analytics enabling flexibility, easy customization and scalability Fosters cross-functional collaboration and improves overall efficiency in clinical research and development WALTHAM, Mass. / Feb 12, 2024 / Business Wire... Read More

Fourth quarter revenue of $696 million; (6)% reported growth; (7)% organic growth; (3)% non-COVID organic growth Fourth quarter GAAP EPS of $0.64; Adjusted EPS from continuing operations of $1.25 Initiates full year 2024 guidance WALTHAM, Mass. / Feb 01, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 The... Read More

WALTHAM, Mass. / Jan 25, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. “I am pleased to welcome Michael Klobuchar and Sophie Vandebroek to Revvity’s board and look forward to their contributions as we execute on our strategic vision,” said Alexis Michas, non-executive chairman of the... Read More

WALTHAM, Mass. / Jan 25, 2024 / Business Wire / The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 10, 2024 to all shareholders of record at the close of business on April 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Jan 09, 2024 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced that it will release its fourth quarter and full year 2023 financial results prior to market open on Thursday, February 1, 2024. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the... Read More

WALTHAM, Mass. / Dec 19, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 42 nd annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 10:30 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page . A replay of the... Read More

WALTHAM, Mass. / Nov 14, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) will present at the 6 th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023 at 9:10 a.m. ET in Miami, FL. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To register, click here . A live audio webcast will be available on the Events section of the Company’s... Read More

Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing operations of $1.18 Updates full year 2023 guidance WALTHAM, Mass. / Oct 30, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY), today reported financial results for the third quarter ended October 1, 2023. The Company reported GAAP earnings per share of $0.08, as compared to $0.67 in... Read More

WALTHAM, Mass. / Oct 26, 2023 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on February 9, 2024 to all shareholders of record at the close of business on January 19, 2024. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

WALTHAM, Mass. / Oct 26, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) today unveils its inaugural 2023 Environmental, Social and Governance (ESG) Report . An in-depth overview of the Company’s ESG strategy, initiatives and performance, the report showcases the Company’s deepening commitment to driving more sustainable solutions, along with a culture of transparency, empowerment and inclusivity. “Revvity’s ESG program... Read More

WALTHAM, Mass. / Oct 09, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2023 financial results prior to market open on Monday, October 30, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call.... Read More

Launch of Pin-point TM base editing reagents improves access to new-generation editing technology Access to the Pin-point system now bridges discovery, preclinical and clinical with the same technology platform Reagent launch puts clinically relevant base editing in the hands of preclinical laboratories seeking to accelerate genomic insights and cell therapy research WALTHAM, Mass. / Sep 26, 2023 / Business Wire / Revvity ,... Read More

IVIS® Spectrum 2 and IVIS SpectrumCT 2 imaging systems — new flagship platforms setting the standard in high-throughput performance and versatility Quantum TM GX3 microCT imaging solution — a high-throughput system with superior spatial resolution and fast, low-dose scanning for diverse in vivo and biological ex vivo... Read More

WALTHAM, Mass. / Aug 23, 2023 / Business Wire / Revvity, Inc. (NYSE: RVTY) today announced it will present at the 2023 Wells Fargo Healthcare Conference, the Baird 2023 Global Healthcare Conference and the Bank of America European Healthcare Conference. 2023 Wells Fargo Healthcare Conference – Boston, MA Wednesday, September 6, 2023 8:00 a.m. ET - Max Krakowiak, senior vice president and chief financial officer Baird 2023... Read More

Revenue of $709 million; (21)% reported growth; (20)% organic growth; 6% non-COVID organic growth GAAP EPS of $0.28; Adjusted EPS from continuing operations of $1.21 Updates full year 2023 guidance WALTHAM, Mass. / Aug 01, 2023 / Business Wire / Revvity, Inc . (NYSE: RVTY), today reported financial results for the second quarter ended July 2, 2023. The Company reported GAAP earnings per share of $0.28, as compared to $1.42... Read More

WALTHAM, Mass. / Jul 21, 2023 / Business Wire / The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 10, 2023 to all shareholders of record at the close of business on October 20, 2023. About Revvity At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science... Read More

Fontus’ easy-to-use software, optimized deck access, verified NGS protocols and reformatting capabilities simplify workflows and improve turnaround times Enables nearly any liquid handling application to be automated Revvity will showcase additional industry-leading diagnostic solutions at 2023 AACC WALTHAM, Mass. / Jul 20, 2023 / Business Wire / Revvity (NYSE: RVTY), today announced the launch of the Fontus™ Automated... Read More

WALTHAM, Mass. / Jul 12, 2023 / Business Wire / Revvity (NYSE: RVTY), today announced that it will release its second quarter 2023 financial results prior to market open on Tuesday, August 1, 2023. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To... Read More

The HIVE CLX Single-Cell RNAseq Solution integrates sample storage and single cell profiling into a robust, instrument-free workflow Studies in innate immunology, infectious diseases and clinical research aided by the HIVE’s capabilities for rare and fragile cell recovery Faster, more reliable results delivered by complementary BeeNetPLUS analysis workflow and HIVE CLX Service offering WALTHAM, Mass. / Jun 29, 2023 /... Read More

Signals Research Suite integrates workflows across biology, chemistry and materials new product development to arm scientists with better data, insights and outcomes Centrally installed and managed, the integrated suite covers the entire Make-Test-Decide lifecycle First solution released by Revvity under the new Revvity Signals Software brand WALTHAM, Mass. / Jun 12, 2023 / Business Wire / Today, Revvity, Inc. (NYSE: RVTY),... Read More